Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 2 December 2019 – On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme, initiated 5 November 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 November 2019 to 3 February 2020.
Since the announcement as of 25 November 2019, the following transactions have been made:
|Accumulated, last announcement||1,315,000||502,958,503|
|25 November 2019||105,000||375.00||39,374,933|
|26 November 2019||105,000||379.45||39,842,774|
|27 November 2019||100,000||380.64||38,063,757|
|28 November 2019||100,000||382.84||38,283,947|
|29 November 2019||100,000||384.07||38,406,648|
|Accumulated under the programme||1,825,000||696,930,562|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 8,206 B shares in the period from 25 November 2019 to 29 November 2019. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 46,760,149 B shares of DKK 0.20, corresponding to 1.9% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 29 November, Novo Nordisk has since 1 February 2019 repurchased a total of 39,648,923 B shares at an average share price of DKK 342.77 per B share equal to a transaction value of DKK 13,590,603,180.
|Anne Margrethe Hauge||+45 4442 email@example.com|
|Ken Inchausti (US)||+1 609 240 firstname.lastname@example.org|
|Peter Hugreffe Ankersen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Mark Joseph Root||+45 3079 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|
Upcoming Life Sciences Events
- August 2020
- ChinaBio® Partnering Forum 2020 Digital
- Biotechgate Digital Partnering Event
- September 2020
- Basel: Pharma-Biotech Product & Company Valuation